• Katia Donadello, Stefano Cristallini, Fabio Silvio Taccone, Sophie Lorent, Jean-Louis Vincent, Daniel de Backer, and Frédérique Jacobs.
• Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
• Int. J. Antimicrob. Agents. 2013 Dec 1; 42 (6): 580-3.

AbstractWe report the case of an immunosuppressed patient with Strongyloides disseminated infection who was successfully treated with the veterinary parenteral form of ivermectin. A kidney transplant recipient developed disseminated infection with Strongyloides stercoralis. Because oral treatment with ivermectin was not possible, subcutaneous ivermectin (75 µg/kg/day, then 200 µg/kg/day) was given for 9 days, with clinical improvement and disappearance of all larvae. Serum ivermectin concentrations were between 15.6 ng/mL and 19.7 ng/mL during the 9 days of therapy; however, drug accumulation (plasma levels >40 ng/mL) 48 h after discontinuation of therapy was associated with the development with encephalopathy. We also review all cases of human disseminated Strongyloides infection treated with parenteral ivermectin.Copyright © 2013 Elsevier B.V. and the International Society of Chemotherapy. Published by Elsevier B.V. All rights reserved.

23 keywords...

hide…